RenovoRx Files 8-K: Procedural Update
Ticker: RNXT · Form: 8-K · Filed: Sep 25, 2024 · CIK: 1574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, procedural
TL;DR
RenovoRx filed an 8-K, but it's just a placeholder with no new info.
AI Summary
RenovoRx, Inc. filed an 8-K on September 25, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific financial figures or details about the nature of the events or exhibits being reported, making it a procedural update.
Why It Matters
This filing indicates RenovoRx, Inc. is fulfilling its reporting obligations with the SEC, but lacks specific operational or financial details for investors to assess.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain new material information that would immediately impact the company's risk profile.
Key Players & Entities
- RenovoRx, Inc. (company) — Registrant
- September 25, 2024 (date) — Filing Date
FAQ
What specific 'Other Events' are being reported by RenovoRx, Inc. in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond listing it as an item information.
What 'Financial Statements and Exhibits' are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information but does not detail their content.
What is the principal executive office address for RenovoRx, Inc.?
The principal executive offices are located at 4546 El Camino Real, Suite B1, Los Altos, CA 94022.
What is the telephone number for RenovoRx, Inc.'s principal executive offices?
The telephone number is (650) 284-4433.
What is the Commission File Number for RenovoRx, Inc.?
The Commission File Number is 001-40738.
Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-09-25 16:10:23
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value RNXT The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex99-1.htm (EX-99.1) — 28KB
- 0001493152-24-038108.txt ( ) — 244KB
- rnxt-20240925.xsd (EX-101.SCH) — 3KB
- rnxt-20240925_lab.xml (EX-101.LAB) — 33KB
- rnxt-20240925_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: September 25, 2024 By: /s/ Shaun R. Bagai Name: Shaun R. Bagai Title: Chief Executive Officer